Corvus Pharmaceuticals Inc
CRVSHealthcare|Biotechnology|USA
$15.67
-0.53 (-3.27%)
Tangible Book
$2.86
Earnings Power
$2.59
About
Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. It believes its proprietary product candidates have broad potential to address immune mediated diseases, inflammatory diseases and cancers. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The company operates in one primary business activity and operate as one reportable segment.
Stock Price
+268.7%(1Y)
Pipeline Summary
10 total trials7
Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
Completed: 6Active: 1Terminated: 1Recruiting: 2
Active Trials (3)
A Dose Escalation Study Evaluating CPI-818 in Relapsed/Refractory T-Cell Lymphoma
NCT03952078T-cell Lymphoma
Phase 1Active
Enrollment: 151 participants
Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma
NCT06561048Peripheral T-Cell Lymphoma, Not Otherwise Specified
Phase 3Recruiting
Enrollment: 150 participants
Study to Evaluate Soquelitinib in Participants With Moderate to Severe AD
NCT07441395Atopic Dermatitis
Phase 2Recruiting
Enrollment: 200 participants
BioScore
3.7/10
Cautious
Ownership
Recent Insider Trades
Moore David ScottBUY
2026-06-1121,700 shares @ $11.53
MILLER RICHARD A MDBUY
2026-05-186,932 shares @ $12.04
ORBIMED ADVISORS LLCSELL
2025-06-271,176,332 shares @ $4.16
Thompson Peter A.SELL
2025-06-271,176,332 shares @ $4.16
Jones William BentonBUY
2024-05-0620,000 shares @ $1.73
Data last updated: Jul 13, 2026, 12:46 PM